Table 2.
The Mean Performances of Diverse Sequences After 5-Fold Cross-Validation† for Predicting 2-Year Relapse
| Volumetric Interest (VOI) | Sequences (Feature Number) | Training Dataset (n = 258) | Validation Dataset (n = 65) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Sen | Spe | Acc | AUC (95% CI) | Sen | Spe | Acc | AUC (95% CI) | ||
| VOItumor | T2 (32) | 0.422 | 0.936 | 0.797 | 0.804(0.744–0.866) | 0.329 | 0.909 | 0.746 | 0.738(0.598–0.882) |
| DWI (21) | 0.343 | 0.926 | 0.762 | 0.769(0.705–0.835) | 0.296 | 0.892 | 0.723 | 0.648(0.493–0.805) | |
| PRE (20) | 0.256 | 0.952 | 0.755 | 0.724(0.654–0.795) | 0.198 | 0.948 | 0.736 | 0.663(0.515–0.814) | |
| AP (22) | 0.294 | 0.938 | 0.756 | 0.784(0.724–0.846) | 0.253 | 0.922 | 0.733 | 0.720(0.583–0.859) | |
| PVP (28) | 0.135 | 0.989 | 0.748 | 0.721(0.654–0.789) | 0.111 | 0.987 | 0.739 | 0.673(0.532–0.817) | |
| TP (24) | 0.459 | 0.948 | 0.810 | 0.846(0.796–0.897) | 0.363 | 0.935 | 0.773 | 0.764(0.641–0.888) | |
| HBP (22) | 0.368 | 0.952 | 0.787 | 0.777(0.714–0.842) | 0.275 | 0.909 | 0.730 | 0.645(0.490–0.802) | |
| 7 sequences (41) | 0.662 | 0.972 | 0.884 | 0.927(0.891–0.968) | 0.494 | 0.909 | 0.792 | 0.823(0.714–0.936) | |
| VOItumor+1cm | T2 (33) | 0.357 | 0.395 | 0.763 | 0.800(0.745–0.859) | 0.395 | 0.904 | 0.761 | 0.722(0.586–0.860) |
| DWI (20) | 0.415 | 0.932 | 0.785 | 0.787(0.724–0.849) | 0.385 | 0.900 | 0.754 | 0.715(0.578–0.853) | |
| PRE (25) | 0.278 | 0.951 | 0.761 | 0.764(0.702–0.827) | 0.265 | 0.939 | 0.749 | 0.710(0.574–0.853) | |
| AP (25) | 0.494 | 0.950 | 0.821 | 0.840(0.788–0.894) | 0.374 | 0.909 | 0.758 | 0.748(0.617–0.881) | |
| PVP (22) | 0.365 | 0.944 | 0.78 | 0.779(0.718–0.842) | 0.308 | 0.922 | 0.748 | 0.696(0.556–0.837) | |
| TP (22) | 0.302 | 0.942 | 0.761 | 0.805(0.749–0.860) | 0.264 | 0.926 | 0.739 | 0.735(0.608–0.863) | |
| HBP (24) | 0.503 | 0.935 | 0.813 | 0.838(0.786–0.891) | 0.427 | 0.900 | 0.767 | 0.729(0.589–0.870) | |
| HBP+T2 (38) | 0.527 | 0.947 | 0.828 | 0.881(0.836–0.928) | 0.429 | 0.926 | 0.786 | 0.764(0.635–0.897) | |
| HBP+T2+AP (33) | 0.720 | 0.995 | 0.917 | 0.988(0.985–0.999) | 0.385 | 0.965 | 0.801 | 0.769(0.635–0.918) | |
| HBP+T2+DWI (39) | 0.585 | 0.960 | 0.854 | 0.899(0.855–0.947) | 0.450 | 0.913 | 0.783 | 0.752(0.616–0.889) | |
| HBP+T2+DWI+AP (33) | 0.368 | 0.978 | 0.806 | 0.839(0.784–0.897) | 0.307 | 0.948 | 0.767 | 0.723(0.583–0.855) | |
| 7 sequences (38) | 0.736 | 0.961 | 0.898 | 0.939(0.908–0.973) | 0.604 | 0.909 | 0.823 | 0.842(0.736–0.951) | |
Note: †The trained and validated performances of each fold for predicting early recurrence is elaborated in Table S4.
Abbreviations: Sen, sensitivity; Spe, specificity; Acc, accuracy; AUC, area under receiver operating characteristic curve; CI, confidence interval; T2, T2-weighted imaging; DWI, diffusion-weighted imaging; Pre, pre-contrasted phase; AP, arterial phase; PVP, portal venous phase; TP, transitional phase; HBP, hepatobiliary phase; VOItumor, the three-dimensional volume of the whole tumor; VOItumor+1cm, the volumetric interest of the whole tumor and the adjacent liver area within 1 cm from the tumor edge.